Each tablet contains: Colchicine USP 500 mcg.
Antigout.
Pharmacology: Pharmacokinetics: Peak plasma concentrations of colchicine are reached within 2 hours of oral use. Colchicine is partially deacetylated in the liver and the unchanged drug and its metabolites are excreted in the bile and undergo intestinal reabsorption. Colchicine is found in high concentrations in leucocytes, kidneys, in liver, and spleen.
Most of the drug is excreted in the urine and this proportion rises in patients with liver disorders. Colchicine is distributed in breast milk.
Colchicine is used for the relief of acute gout and for the prophylaxis of acute attacks, particularly during the first few months of treatment with allopurinol or uricosurics.
Colchicine also has an antimitotic action. It has also been used in several other conditions including amyloidosis, Behçet's syndrome, familial Mediterranean fever, idiopathic thrombocytopenic purpura, pericarditis, primary biliary cirrhosis, and pyoderma gangrenosum.
Colchicine is used for the relief of acute gout for the prophylaxis of acute attacks, particularly during the first few months of treatment with allopurinol or uricosurics. Colchicine produces a dramatic response in acute gout, probably by reducing the inflammatory reaction to urate crystals; this effect might be due to several actions including decreased leucocyte mobility. It is not an analgesic and has no effect on blood concentrations of uric acid, or on the excretion of uric acid. Colchicine also has an antimitotic action. Colchicine has also been used in several other conditions including amyloidosis, Behçet's syndrome, familial Mediterranean fever, idiopathic thrombocytopenic purpura, pericarditis, primary biliary cirrhosis, and pyoderma gangrenosum. Although colchicine 1 mg orally, followed by 500 micrograms every 2 to 3 hours, is recommended for the treatment of acute gout, many rheumatologists consider this excessive a low-dose regimen of 500 micrograms no more than 3 times daily has been advocated in preference.
Colchicine is contraindicated in pregnancy because of animal teratogenicity. However it has been used during pregnancy in women with familial Mediterranean fever. There was no increase in abnormality rate of the newborns and no problems were detected in 130 offsprings.
Colchicine should be given with great care to elderly or debilitated patients who may be particularly susceptible to cumulative toxicity. It should also be used with caution in patients with cardiac, hepatic, renal, or gastrointestinal disease. Colchicine should be avoided in patients with blood disorders. It should also generally be avoided in pregnancy since it is known to be teratogenic in animals and there has also been some suggestions of a risk of fetal chromosome damage in humans.
The most frequent adverse effects of oral colchicine are those involving the gastrointestinal tract and may be associated with its antimitotic action. Diarrhoea, nausea, vomiting, and abdominal pain are often the first signs of toxicity and are usually an indication that colchicine therapy should be stopped or the dose reduced. Larger dose may cause profuse diarrhoea, gastrointestinal haemorrhage, skin rashes, and renal and hepatic damage. Rarely, bone marrow depression with agranulocytosis, thrombocytopenia, and aplastic anemia have occurred on prolonged treatment as have peripheral neuropathy, myopathy, rashes, and alopecia.
Use of colchicine with clarithromycin, erythromycin, or tolbutamide may cause colchicine toxicity. Thiazide diuretics may increase serum uric acid and interfere with the activity of colchicine. Muscle disorders have been reported when colchicine is used with ciclosporin. Colchicine may impair the absorption of Vitamin B12.
Store at temperatures not exceeding 30°C.
Protect from light.
M04AC01 - colchicine ; Belongs to the class of preparations with no effect on uric acid metabolism. Used in the treatment of gout.
Acugout tab 500 mcg
100's
Sign Out
